PMCB PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.…
Industry Peers
BiotechnologyKey Statistics
About PharmaCyte Biotech (NASDAQ: PMCB)
›
PharmaCyte Biotech (NASDAQ: PMCB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 6.680 USD on 13 November 2026, up 684.6% over 52 weeks. Its 52-week range is 0.2500 USD to 8.175 USD: the price is 18.3% below the high and 2572.0% above the low.
Its market capitalisation is 3.77M USD.
PharmaCyte Biotech reports return on equity of -55.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 30.51M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.